Welcome to our dedicated page for Stoke Therapeutics news (Ticker: STOK), a resource for investors and traders seeking the latest updates and insights on Stoke Therapeutics stock.
Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company that develops RNA-based medicines to restore protein expression in severe genetic diseases. Its news flow is closely tied to the progress of its antisense oligonucleotide programs, particularly zorevunersen for Dravet syndrome and STK-002 for Autosomal Dominant Optic Atrophy (ADOA).
Investors following STOK news can expect regular updates on clinical development milestones. These include announcements on the global Phase 3 EMPEROR study of zorevunersen in children and adolescents with Dravet syndrome, multi-year data from open-label extension studies, and analyses comparing treated patients with natural history data. Stoke also reports on natural history research such as the FALCON study in ADOA, which informs the design of interventional trials like the OSPREY Phase 1 study of STK-002.
Regulatory and collaboration developments are another important category of news. Stoke highlights regulatory designations for zorevunersen, including orphan drug, rare pediatric disease, and Breakthrough Therapy Designation, as well as its strategic collaboration with Biogen, under which the companies jointly advance zorevunersen for Dravet syndrome with defined regional commercialization rights.
Corporate and financial updates appear in press releases and are often paired with SEC filings. These items cover quarterly financial results, cash runway commentary, stock-based inducement grants under Nasdaq Listing Rule 5635(c)(4), and participation in major healthcare and investor conferences. Webcasts and conference calls for analysts and investors are also announced through news releases.
For anyone researching STOK, the news stream provides context on how Stoke Therapeutics is advancing its TANGO antisense platform, executing clinical trials in rare neurological and ophthalmic diseases, and managing its partnerships and capital to support ongoing development.
Stoke Therapeutics (NASDAQ: STOK) announced on October 6, 2025 that Ian F. Smith has been appointed Chief Executive Officer after serving as Interim CEO since March 2025 and as a board member and advisor since 2023. Arthur Tzianabos resumes as Chairman. The company noted the start of its pivotal Phase 3 EMPEROR study of zorevunersen for Dravet syndrome and a February 2025 collaboration with Biogen that gives Stoke U.S., Canada, and Mexico rights while Biogen holds rest-of-world rights. Stoke also began a second clinical program in Autosomal Dominant Optic Atrophy.
Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine, has granted 135,300 stock options to five new employees as inducement awards. The options were granted at an exercise price of $23.40 per share, matching the company's closing stock price on September 15, 2025.
The options will vest over 4 years, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. These 10-year options were granted under the company's 2023 Inducement Plan as employment incentives in accordance with Nasdaq Listing Rule 5635(c)(4).
Stoke Therapeutics (NASDAQ:STOK), a biotechnology company focused on RNA medicine, has announced upcoming presentations at two major investor conferences in September 2025. The company's Interim CEO Ian F. Smith will present at the Cantor Global Healthcare Conference on September 4 at 3:20 p.m. ET and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9 at 1:05 p.m. ET.
Stoke is developing zorevunersen, a first-in-class potential treatment for Dravet syndrome. Investors can access live webcasts and replays of both presentations through the company's investor relations website.
Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine, has announced inducement grants of stock options to two new employees. The company's newly appointed Chief Regulatory Officer, Elizabeth Mellen, received options to purchase 270,000 shares at an exercise price of $18.21 per share. Additionally, another new employee received options to purchase 14,000 shares at the same exercise price.
The options will vest over a 4-year period, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. All options have a 10-year term and are subject to continued employment and the 2023 Inducement Plan terms.
Stoke Therapeutics (NASDAQ:STOK) reported Q2 2025 financial results and significant clinical progress. The company achieved key milestones including dosing the first patient in the Phase 3 EMPEROR study of zorevunersen for Dravet syndrome and initiating a Phase 1 OSPREY study of STK-002 for ADOA treatment.
Financial highlights include a strong cash position of $355.0 million, expected to fund operations until mid-2028. Q2 2025 revenue reached $13.8 million, with a net loss of $23.5 million ($0.40 per share). The company reported positive 3-year open-label extension data for zorevunersen, showing durable seizure reductions and improved cognition in Dravet syndrome patients.
R&D expenses increased to $25.9 million in Q2 2025 from $21.1 million in Q2 2024, while G&A expenses rose to $15.3 million from $13.0 million year-over-year, reflecting increased personnel and launch preparation costs.
Stoke Therapeutics (NASDAQ:STOK), a biotechnology company focused on RNA medicine and protein expression restoration, has scheduled a webcast and conference call for August 12, 2025, at 4:30 p.m. ET. The event will cover the company's second quarter 2025 business and financial updates.
The company's lead investigational medicine, zorevunersen, is being developed as a potential first-in-class disease-modifying treatment for Dravet syndrome. Research analysts can register for Q&A participation, while other participants can access the listen-only webcast through the company's investor relations website. The webcast recording will be available for at least 90 days after the event.
Stoke Therapeutics (NASDAQ:STOK), a biotechnology company focused on RNA medicine, announced its participation in the upcoming Canaccord Genuity 45th Annual Growth Conference. Interim CEO Ian F. Smith will deliver a presentation on Wednesday, August 13, 2025, at 11:30 a.m. ET.
The company, which is developing zorevunersen as a potential first-in-class treatment for Dravet syndrome, will make the presentation available via live webcast on their investor relations website, with an archived replay accessible afterward.
Stoke Therapeutics (Nasdaq: STOK), a biotechnology company focused on RNA medicine, has announced inducement grants to three new employees, including newly-appointed Chief People Officer Sara Den Besten. The company granted Ms. Den Besten options to purchase 260,000 shares of common stock at $11.75 per share, while two other employees received options to purchase an aggregate of 130,000 shares.
All options have a 10-year term and will vest over a 4-year period, with 25% vesting after one year and the remainder vesting monthly over the following 36 months. The grants were made under the company's 2023 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Stoke Therapeutics (NASDAQ: STOK), a biotechnology company focused on RNA medicine to restore protein expression, announced that Interim CEO Ian F. Smith will present at the Jefferies Global Healthcare Conference on June 4, 2025, at 1:25 p.m. ET. The company's lead investigational medicine, zorevunersen, is being developed as a potential first-in-class disease-modifying treatment for Dravet syndrome. A live webcast and replay of the presentation will be accessible through Stoke's investor relations website.
FAQ
What is the current stock price of Stoke Therapeutics (STOK)?
What is the market cap of Stoke Therapeutics (STOK)?
